Floating “Wall of Wind Turbines’ Gets Approval

A Norwegian company is developing an innovative wind energy concept called the “Windcatcher,” an offshore floating facility. Instead of using a few giant turbines, the Windcatcher will comprise hundreds of small turbines packed together. This visionary project is spearheaded by Wind Catching Systems (WCS).

The Windcatcher has reached a significant milestone by receiving certification from DNV, a leading global classification agency. This certification confirms the technical feasibility of the design, allowing the project to advance to the next stage.

The Windcatcher concept involves a floating offshore wind farm that uses multiple small 1MW turbines instead of traditional large turbines. These innovative turbines can capture 2.5 times more energy per square meter of wind flow compared to standard three-blade turbine designs. The unique design, resembling a “floating wall of wind,” aims to double energy output.

The company plans for the Windcatcher to generate 40MW of power in the future. In the long term, WCS aims to add units with a capacity of up to 126 MW.

The Windcatcher is designed to withstand the harsh conditions of the open sea. It is a modular system that can be scaled up or down based on energy needs. Each unit connects to a central substation, which transmits the electricity to the grid.

This is a very interesting concept. One of the issues surrounding wind turbines is there tendency to kill large amounts of birds. Hopefully these are big enough for flocks of birds to recognize that they need to go around it.

Electric Butterflies

A new study has revealed that the electrostatic field generated by butterflies and moths in flight enables them to attract pollen grains from flowers across air gaps several centimeters wide.

Researchers from the University of Bristol found that the static electricity carried by butterflies and moths varies among species, influenced by their ecology, including the type of flowers they visit, whether they are diurnal or nocturnal, and their habitat. The findings, published in the Journal of the Royal Society Interface, suggest that this electric field enhances their efficiency and effectiveness as pollinators.

While it was known that animals like bees and hummingbirds use static electricity to collect pollen, it was unclear if this applied to butterflies and moths. “We set out to test this idea,” says lead author Dr. Sam England from Bristol’s School of Biological Sciences, “to see if butterflies and moths also accumulate charge, and if so, whether this charge is enough to attract pollen from flowers onto their bodies.”

The study examined 269 butterflies and moths across 11 species from five continents, each in different ecological niches. This allowed the researchers to compare the static charge and determine if ecological variables influenced it.

Dr. England explains, “We’ve discovered that butterflies and moths accumulate so much static electricity when flying, that pollen is literally pulled through the air towards them as they approach a flower,”” This means they don’t need to touch flowers to pollinate them, which makes them highly efficient pollinators.

Expired Life Jackets Recycled

United Airlines has partnered with the German upcycling company B2L to repurpose 900 pounds of expired life jackets into stylish bags. According to aviation safety regulations, life jackets on planes must be replaced every 8 to 10 years, resulting in United’s Boeing 737 fleet alone generating over 19,000 expired jackets annually.

The collaboration aims to reduce landfill waste and the airline’s carbon footprint by converting these jackets into various products such as laundry bags, laptop bags, beach bags, and backpacks. This initiative emerged when Erin Taylor, an environmental affairs manager at United, sought a more creative and sustainable solution for disposing of the expired jackets.

The first year of this partnership was successful, garnering positive reviews and leading to a contract renewal with increased production for the following year. If not upcycled, these life jackets would take centuries to decompose.

HIV Drug Reduces Carbon Emissions

A groundbreaking report has revealed that changing the ingredients or manufacturing methods of widely used medications can significantly reduce carbon emissions.

The study found a reduction of 26 million tons of CO2, equivalent to the entire carbon footprint of Geneva for ten years. This reduction has already been achieved.

The HIV treatment dolutegravir (DTG) is used by 24 million people worldwide. Over 110 low and middle-income countries have adopted DTG as the preferred treatment option. Rapid voluntary licensing of the medicine, including its pediatric version, to over a dozen generic manufacturers, has significantly reduced prices. It’s estimated that 1.1 million lives will be saved from HIV/AIDS-related deaths by 2027.

DTG’s predecessor, efavirenz, contained 1200 milligrams of active ingredients, while DTG contains 650 milligrams of just one compound. This small difference was enough to reduce the medication’s carbon footprint by a factor of 2.6.

Unitaid, a global public-private partnership that invests in new health products for low and middle-income countries, published the report “Milligrams to Megatons.” It is the first research to compare carbon footprints between commonly used medications. The authors noted that the reduction in carbon footprint surpasses many climate mitigation achievements in health and other sectors.

Since DTG entered production in 2017, 2.6 million fewer tons of CO2 have entered the atmosphere each year compared to if efavirenz was still the standard treatment. The global medical sector’s carbon emissions are about 5% of the global total, larger than the emissions of many big countries and 2.5 times as much as aviation.

“This report shows that we can achieve significant health improvements while also reducing carbon emissions. By adopting innovative practices and prioritizing sustainability, we can ensure that medicines like DTG are effective and environmentally responsible,” Vincent Bretin, Director of Unitaid’s Results and Climate Team, told Health Policy Watch.

Diabetes-Reversing Drug

In a new study published in Science Translational Medicine, A new drug tested in mice increased the number of beta cells in the pancreas sevenfold, effectively reversing diabetes symptoms.

This achievement, described as a “functional diabetes cure,” is unprecedented in drug development.

In just three months, the mice’s cells began producing insulin again through a combination of two drugs: harmine, which inhibits the enzyme DYRK1A, and a GLP1 receptor agonist, found in the diabetes drug Ozempic.

Researchers from Mount Sinai and City of Hope tested their drug by injecting human beta cells into mice and then administering the treatment. The beta cells increased sevenfold in three months, with diabetes symptoms disappearing within a month after treatment stopped.

Previous attempts at this concept involved converting stem cells into human pancreas beta cells in vitro and transplanting them into diabetes patients, a costly and time-consuming procedure.

“This is the first time scientists have developed a drug treatment that increases adult human beta cell numbers in vivo,” said Dr. Adolfo Garcia-Ocaña, corresponding author of the study. “This research brings hope for future regenerative therapies to treat the hundreds of millions of people with diabetes.” Harmine alone has undergone a phase 1 clinical trial in humans for safety and tolerability, but DYRK1A inhibitors have not.